Africa to get state-of-art HIV drugs for US$ 75 a year

Global Fund Observer Newsletter, Issue 321, 4 October 2017

16 pp. 578 kB

In what has been hailed as a “breakthrough” and a “game changer,” a pricing agreement between the Bill and Melinda Gates Foundation and two generic drug companies (Mylan Laboratories and Aurobindo Pharma, both based in India), will result in significant savings in the cost of antiretrovirals (ARVs). As a result of the agreement, starting in 2018 a state-of-the-art fixed dose combination ARV regimen will be available in 92 developing nations at a maximum cost of US$ 75 per patient per year.

(Visited 23 times, 1 visits today)
This entry was posted in Essential Medicines, General, HIV - AIDS - STI. Bookmark the permalink.